Annual report
4564.TEDINET S100R52T
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.0bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.1bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥795m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥31m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥74m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥96m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥566m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.86 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.73 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.9 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4.04 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥16.96 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥25.81 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥30.32 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 60 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 67 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 66 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 62 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 63 | at 2019-03-31d | Cons. | Number of employees |
| Operating income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥949m | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥374m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥418m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥575m | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥297m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-5.8 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.13 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.05 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2.58 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥14.53 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥23.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥25.75 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 52.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 192,643,700 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 151,557,400 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 28 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 36 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 35 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 32 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 37 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 51
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥19m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥238,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥238,000 |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥344m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥381m |
| Cancer Precision Medical Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2m |
| Cancer Precision Medical Businessreportable segment | employees | at 2023-03-31 | 32 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2023-03-31 | ¥714m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥34m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥490,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2023-03-31 | 28 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥238,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2023-03-31 | ¥1.1bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥691m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥2m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥238,000 |
| —segment total | segment assets | at 2023-03-31 | ¥1.9bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | −¥725m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥952,000 |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥683m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥368m |
| Cancer Precision Medical Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥468m |
| Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2022-03-31 | ¥1.0bn |
| Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥49m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥166,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2022-03-31 | ¥2.3bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥1.6bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥469m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9m |
| —segment total | segment assets | at 2022-03-31 | ¥3.4bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2023-03-31 | 28 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,159
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 238000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -238000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 9372000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 1125769000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 1135142000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -238000 | JPY |
| Net sales | CurrentYearDuration | 1134903000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -690746000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -34385000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | -725131000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -381283000 | JPY |
| Operating income | CurrentYearDuration | -1106415000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 1141080000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 714447000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 1855527000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | -344089000 | JPY |
| Assets | CurrentYearInstant | 1511438000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | － | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Depreciation segment information | CurrentYearDuration | － | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 490000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 1652000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReportableSegmentsMember | 2142000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 19411000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 21553000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 50183000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 467740000 | JPY |
| Impairment loss el | Prior1YearDuration_UnallocatedAmountsAndEliminationMember | 29850000 | JPY |
| Impairment loss el | Prior1YearDuration | 547773000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 490000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 1652000 | JPY |
| Impairment loss el | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | 19411000 | JPY |
| Impairment loss el | CurrentYearDuration | 21553000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 1161270000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 297298000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 38000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 73000 | JPY |
| Raw materials and supplies | Prior1YearInstant_NonConsolidatedMember | 1235000 | JPY |
| Raw materials and supplies | CurrentYearInstant_NonConsolidatedMember | 376000 | JPY |
| Advance payments trade | Prior1YearInstant_NonConsolidatedMember | 19090000 | JPY |
| Advance payments trade | CurrentYearInstant_NonConsolidatedMember | 16143000 | JPY |
| Prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 8970000 | JPY |
| Prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 6745000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | Prior1YearInstant_NonConsolidatedMember | 250000000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 100000000 | JPY |
| Income taxes receivable | Prior1YearInstant_NonConsolidatedMember | 23000 | JPY |
| Income taxes receivable | CurrentYearInstant_NonConsolidatedMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |